Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Table 4 Multivariable analysis of factors associated with an increased risk for major adverse event within 30 days after TAVI

	OR [95% CI]	p value
Mean daily δ blood glucose, per quartile^a	1.83 [1.19–2.83]	0.006
Hyperglycemia^b	0.84 [0.31–2.27]	0.73
Logistic EuroSCORE (per % of increase)	1.03 [0.99–1.06]	0.12
NYHA class III or IV	2.00 [0.83–4.81]	0.12
Obesity (BMI ≥ 30 kg m⁻²)	0.22 [0.05–1.05]	0.06
Hypertension	1.64 [0.57–4.72]	0.36

Chi2 = 6.13, p = 0.63 for the Hosmer–Lemeshow goodness-of-fit test
BMI, body mass index; NYHA, New York Heart Association; OR [95% CI], odds ratio [95% confidence interval]
^aStudy population divided into 4 equal groups according to the quartile of mean daily δ blood glucose defined by values < 3.0, 3.0–4.3, 4.4–5.7, > 5.7 mmol l⁻¹, respectively
^bPost-procedural hyperglycemia was defined as two consecutive blood glucose values ≥ 8.2 mmol l⁻¹

ISSN: 1475-2840